Print

New ANDA Cases

Case Name Date Filed Judge Drug Patent No(s).
Sanofi-Aventis U.S. LLC v. Biocon Ltd., 17-0003 (D. Del.) Jan. 3, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410; 9,186,346
Sanofi-Aventis U.S. LLC v. Impax Labs., Inc., 17-0004 (D. Del.) Jan. 3, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410; 9,186,346
Fresenius Kabi USA, LLC v. Sagent Pharms., Inc., 17-0011 (D. Del.) Jan. 4, 2017 Hon. Leonard P. Stark Naropin® (ropivacaine hydrochloride for injection) 8,118,802; 8,162,915
Par Pharm., Inc. v. Sunovion Pharms., Inc., 17-10016 (D. Mass.) Jan. 4, 2017 Hon. George A. OToole, Jr. Latuda® (lurasidone hydrochloride tablets) 8,729,085; 8,883,794; RE45,573
Silvergate Pharms., Inc. v. Bionpharma, Inc., 17-0016 (D. Del.) Jan. 5, 2017 Hon. Sue L. Robinson Epaned® (enalapril maleate oral solution) 8,778,366
Sanofi-Aventis U.S. LLC v. Teva Pharms. USA, Inc., 17-0018 (D. Del.) Jan. 5, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410
Sanofi-Aventis U.S. LLC v. Breckenridge Pharm., Inc., 17-0019 (D. Del.) Jan. 5, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410; 8,802,735; 9,186,346
Famy Care Ltd. v. Allergan, Inc., IPR2017-00566 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,648,048
Famy Care Ltd. v. Allergan, Inc., IPR2017-00567 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,629,111
Famy Care Ltd. v. Allergan, Inc., IPR2017-00568 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,633,162
Famy Care Ltd. v. Allergan, Inc., IPR2017-00569 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 9,248,191
Famy Care Ltd. v. Allergan, Inc., IPR2017-00570 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,642,556
Famy Care Ltd. v. Allergan, Inc., IPR2017-00571 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,685,930
Teva Pharms. USA, Inc. v. Allergan, Inc., IPR2017-00576 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,685,930
Teva Pharms. USA, Inc. v. Allergan, Inc., IPR2017-00578 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,629,111
Teva Pharms. USA, Inc. v. Allergan, Inc., IPR2017-00579 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,642,556
Teva Pharms. USA, Inc. v. Allergan, Inc., IPR2017-00583 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,633,162
Teva Pharms. USA, Inc. v. Allergan, Inc., IPR2017-00585 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,648,048
Teva Pharms. USA, Inc. v. Allergan, Inc., IPR2017-00586 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,648,048
Akorn, Inc. v. Allergan, Inc., IPR2017-00594 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,685,930
Akorn, Inc. v. Allergan, Inc., IPR2017-00596 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,629,111
Akorn, Inc. v. Allergan, Inc., IPR2017-00598 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,642,556
Akorn, Inc. v. Allergan, Inc., IPR2017-00599 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,633,162
Akorn, Inc. v. Allergan, Inc., IPR2017-00600 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 8,648,048
Akorn, Inc. v. Allergan, Inc., IPR2017-00601 (PTAB) Jan. 6, 2017 N/A Restasis® (cyclosporine ophthalmic emulsion) 9,248,191
Complex Innovations, LLC v. AstraZeneca AB, IPR2017-00631 (PTAB) Jan. 9, 2017 N/A Symbicort® (budesonide / formoterol fumarate dihydrate aerosol inhalation) 7,759,328
Sanofi-Aventis U.S. LLC v. Mylan Pharms. Inc., 17-0024 (D. Del.) Jan. 10, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410; 8,802,735; 9,186,346
Sanofi-Aventis U.S. LLC v. MSN Labs. Private Ltd., 17-0027 (D. Del.) Jan. 10, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410; 8,802,735; 9,186,346
Sanofi-Aventis U.S. LLC v. Hetero USA Inc., 17-0031 (D. Del.) Jan. 11, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410; 8,802,735; 9,186,346
Sanofi-Aventis U.S. LLC v. Zydus Pharms. (USA) Inc, 17-0034 (D. Del.) Jan. 11, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 8,802,735; 9,186,346
Sanofi-Aventis U.S. LLC v. Amneal Pharms. LLC, 17-0039 (D. Del.) Jan. 12, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410; 8,802,735; 9,186,346
Sanofi-Aventis U.S. LLC v. Par Pharm., Inc., 17-0040 (D. Del.) Jan. 12, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410; 8,802,735; 9,186,346
Sanofi-Aventis U.S. LLC v. Mylan Pharms. Inc., 17-0005 (N.D.W.V.) Jan. 12, 2017 Hon. Irene M. Keeley Aubagio® (teriflunomide tablets) 6,794,410; 8,802,735; 9,186,346
Abbvie Inc. v. Aurobindo Pharma Ltd., 17-0047 (D. Del.) Jan. 13, 2017 Hon. Richard G. Andrews Kaletra® (lopinavir / ritonavir tablets) 7,148,359; 7,364,752; 8,025,899; 8,268,349; 8,309,613; 8,377,952; 8,399,015; 8,470,347; 8,691,878
Novartis AG v. Aurobindo Pharma Ltd., 17-0048 (D. Del.) Jan. 13, 2017 Hon. Leonard P. Stark Gilenya® (fingolimod capsules) 5,604,229
Monosol RX, Inc. v. Biodelivery Sciences Int’l, Inc., 17-0246 (D.N.J.) Jan. 13, 2017 Hon. Brian R. Martinotti Belbuca® (buprenorphine buccal film) 8,765,167
Teva Pharms. USA, Inc. v. Sandoz Inc., 17-0275 (D.N.J.) Jan. 13, 2017 Hon. Freda L. Wolfson Copaxone® (glatiramer acetate injection) 9,155,775
Reckitt Benckiser LLC v. Amneal Pharms. LLC, 17-0304 (D.N.J.) Jan. 13, 2017 Hon. Renee Marie Bumb Mucinex® DM (guaifenesin / dextromethorphan hydrobromide extended-release tablets) 6,372,252; 6,955,821; 7,838,032
Teva Pharms. USA, Inc. v. Synthon Pharms. Inc., 17-0345 (S.D.N.Y.) Jan. 17, 2017 Hon. Lorna G. Schofield Copaxone® (glatiramer acetate injection) 9,155,775
Teva Pharms. USA, Inc. v. Mylan Pharms. Inc., 17-0007 (S.D.N.Y.) Jan. 17, 2017 Hon. Irene M. Keeley Copaxone® (glatiramer acetate injection) 9,155,775
Otsuka Pharm. Co., Ltd. v. Mylan N.V., 17-0392 (D.N.J.) Jan. 19, 2017 Hon. Jerome B. Simandle Abilify® (aripiprazole tablets) 9,387,182
Novartis AG v. Aurobindo Pharma Ltd., 17-0389 (D. Del.) Jan. 19, 2017 Hon. Claire C. Cecchi Gilenya® (fingolimod capsules) 5,604,229
Mylan Institutional Inc. v. Fresenius Kabi USA, LLC, IPR2017-00643 (PTAB) Jan. 19, 2017 N/A Levothyroxine sodium 9,168,238
Mylan Institutional Inc. v. Fresenius Kabi USA, LLC, IPR2017-00644 (PTAB) Jan. 19, 2017 N/A Levothyroxine sodium 9,168,239
Mylan Institutional Inc. v. Fresenius Kabi USA, LLC, IPR2017-00645 (PTAB) Jan. 19, 2017 N/A Levothyroxine sodium 9,006,289
Valeant Pharms. Luxembourg S.A.R.L. v. Zydus Pharms. (USA), Inc., 17-0449 (D.N.J.) Jan. 20, 2017 Hon. Peter G. Sheridan Cardizem LA® (diltiazem hydrochloride extended-release tablets) 6,923,984
Aralez Pharms. Inc. v. Teva Pharms. USA, Inc., 17-0071 (E.D. Tex.) Jan. 23, 2017 Hon. Rodney Gilstrap Yosprala® (aspirin / omeprazole delayed-release tablets) 6,926,907; 8,206,741; 9,364,439; 9,539,214
Sanofi-Aventis U.S. LLC v. Emcure Pharms. Ltd., 17-0070 (D. Del.) Jan. 25, 2017 Hon. Gregory M. Sleet Aubagio® (teriflunomide tablets) 6,794,410
Shionogi Inc. v. Aurobindo Pharma Ltd., 17-0072 (D. Del.) Jan. 25, 2017 Hon. Sue L. Robinson Fortamet® (metformin extended-release tablets) 6,790,459; 6,866,866
Amneal Pharms. LLC v. Teva Pharms. USA, Inc., 17-0074 (D. Del.) Jan. 25, 2017 Hon. Gregory M. Sleet Copaxone® (glatiramer acetate injection) 9,155,775
Teva Pharms. USA, Inc. v. Dr. Reddy’s Labs., Ltd., 17-0517 (D.N.J.) Jan. 25, 2017 Hon. Freda L. Wolfson Copaxone® (glatiramer acetate injection) 9,155,775
Teva Pharms. USA, Inc. v. Amneal Pharms. LLC, 17-0416 (E.D.N.Y.) Jan. 25, 2017 Hon. Joan M. Azrack Copaxone® (glatiramer acetate injection) 9,155,775
Dow Pharm. Sciences, Inc. v. Taro Pharms. U.S.A., Inc., 17-0544 (D.N.J.) Jan. 26, 2017 Hon. Stanley R. Chesler Onexton® (benzoyl peroxide / clindamycin phosphate topical gel) 9,504,704
Aptalis Pharma US, Inc. v. Zydus Pharms. (USA) Inc., 17-0630 (D.N.J.) Jan. 30, 2017 Hon. Mary L. Cooper Canasa® (mesalamine rectal suppositories) 7,541,384; 8,217,083; 8,436,051
Momenta Pharms., Inc. v. Teva Pharms. USA, Inc., 17-0109 (D. Del.) Feb. 2, 2017 Hon. Gregory M. Sleet Copaxone® 40 (glatiramer acetate) 9,155,775
Pfizer Inc. v. Torrent Pharms. Ltd., 17-0112 (D. Del.) Feb. 2, 2017 Hon. Gregory M. Sleet Toviaz® (fesoterodine fumarate extended-release tablets) 6,858,650
Argentum Pharms. LLC v. Cipla Ltd., IPR2017-00807 (PTAB) Feb. 2, 2017 N/A Dymista® (azelastine hydrochloride / fluticasone propionate nasal spray) 8,168,620
Amgen Inc. v. Mylan Pharms. Inc., 17-0113 (D. Del.) Feb. 3, 2017 Hon. Gregory M. Sleet Sensipar® (cinacalcet hydrochloride tablets) 9,375,405
Biodelivery Sciences Int’l, Inc. v. Teva Pharms. USA Inc., 17-0118 (D. Del.) Feb. 3, 2017 Hon. Gregory M. Sleet Belbuca® (buprenorphine buccal film) 7,579,019; 8,147,866
Dow Pharm. Sciences, Inc. v. Perrigo UK Finco Ltd., 17-0754 (D.N.J.) Feb. 3, 2017 Hon. Stanley R. Chesler, Onexton® (benzoyl peroxide / clindamycin phosphate topical gel) 8,288,434; 9,504,704
Apotex Inc. v. Novartis A.G., IPR2017-00854 (PTAB) Feb. 3, 2017 N/A Gilenya® (fingolimod capsules) 9,187,405
Biomarin Pharm. Inc. v. Dr. Reddy’s Labs., Inc., 17-0774 (D.N.J.) Feb. 6, 2017 Hon. Michael A. Shipp Kuvan® (sapropterin dihydrochloride packets) 7,566,714; 7,612,073; 8,067,416; RE43,797; 9,216,178; 9,433,624
Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 17-0864 (D.N.J.) Feb. 8, 2017 Hon. Jose L. Linares Narcan® (naloxone hydrochloride nasal spray) 9,468,747
Actavis Labs. FL, Inc., v. Janssen Oncology, Inc., IPR2017-00853 (PTAB) Feb. 8, 2017 N/A Zytiga® (abiraterone acetate tablets) 8,822,438
Iceutica Pty Ltd. v. Lupin Ltd., 17-0394 (D. Md.) Feb. 10, 2017 Hon. Marvin J. Garbis Vivlodex® (meloxicam capsules) 9,526,734
AstraZeneca Pharms. LP v. Dr. Reddy’s Labs., Inc., 17-0926 (D.N.J.) Feb. 10, 2017 Hon. Renee Marie Bumb Faslodex® (fulvestrant for injection) 6,774,122; 7,456,160; 8,329,680; 8,466,139
Pfizer Inc. v. Micro Labs USA Inc., 17-0158 (D. Del.) Feb. 14, 2017 Hon. Leonard P. Stark Xeljanz® (tofacitinib tablets) 6,965,027; 7,301,023; RE41,783
Pfizer Inc. v. C.P. Sun Pharm. Indus. Ltd., 17-0159 (D. Del.) Feb. 14, 2017 Hon. Leonard P. Stark Xeljanz® (tofacitinib tablets) 6,965,027
Sumitomo Dainippon Pharma Co., Ltd. v. MSN Labs. Private Ltd., 17-1010 (D.N.J.) Feb. 14, 2017 Hon. Stanley R. Chesler Latuda® (lurasidone hydrochloride tablets) 5,532,372
Eli Lilly and Co. v. TWi Pharms., Inc., 17-0491 (S.D. Ind.) Feb. 15, 2017 Hon. Richard L. Young Axiron® (testosterone metered transdermal solution) 8,435,944; 8,993,520; 9,180,194; 8,419,307; 8,177,449; 8,807,861; 9,289,586
Wyeth LLC v. Apotex Inc., 17-0168 (D. Del.) Feb. 16, 2017 Vacant Judgeship Advil PM® (ibuprofen / diphenhydramine hydrochloride capsules) 8,883,849; 9,155,718
Eli Lilly and Co. v. TWi Pharms., Inc., 17-0174 (D. Del.) Feb. 17, 2017 Hon. Leonard P. Stark Axiron® (testosterone metered transdermal solution) 8,435,944; 8,993,520; 9,180,194; 8,419,307; 8,177,449; 8,807,861; 9,289,586
Innopharma Licensing, LLC v. AstraZeneca AB, IPR2017-00900 (PTAB) Feb. 17, 2017 N/A Faslodex® (fulvestrant for injection) 8,329,680
Innopharma Licensing, LLC v. AstraZeneca AB, IPR2017-00904 (PTAB) Feb. 17, 2017 N/A Faslodex® (fulvestrant for injection) 6,774,122
Innopharma Licensing, LLC v. AstraZeneca AB, IPR2017-00905 (PTAB) Feb. 17, 2017 N/A Faslodex® (fulvestrant for injection) 8,466,139
Amgen Inc. v. Zydus Pharms. (USA) Inc., 17-0183 (D. Del.) Feb. 21, 2017 Hon. Gregory M. Sleet Sensipar® (cinacalcet hydrochloride tablets) 9,375,405
Gilead Sciences, Inc. v. Mylan Pharms. Inc., 17-0187 (D. Del.) Feb. 22, 2017 Hon. Richard G. Andrews Tybost® (cobicistat tablets) 8,148,374
Orexo AB v. Actavis Elizabeth LLC, 17-0205 (D. Del.) Feb. 28, 2017 Hon. Gregory M. Sleet Suboxone® (buprenorphine / naloxone tablets) Subutex® (buprenorphine tablets) 8.454,996
Purdue Pharma L.P. v. Amneal Pharms., LLC, 17-0210 (D. Del.) Mar. 1, 2017 Hon. Richard G. Andrews OxyContin® (oxycodone hydrochloride extended-release tablets) 9,492,392; 9,492,393; 9,522,919
Jazz Pharms., Inc. v. Amneal Pharms., LLC, 17-1440 (D.N.J.) Mar. 1, 2017 Hon. Esther Salas Xyrem® (sodium oxybate oral solution) 9,486,426
Pfizer Inc. v. Prinston Pharm. Inc., 17-0213 (D. Del.) Mar. 2, 2017 Hon. Leonard P. Stark Xeljanz® (tofacitinib tablets) 6,965,027; 7,301,023
Pfizer Inc. v. Zydus Pharms. (USA), Inc., 17-0214 (D. Del.) Mar. 2, 2017 Hon. Leonard P. Stark Xeljanz® (tofacitinib tablets) 6,965,027; 7,301,023; RE41,783
Novo Nordisk Inc. v. Teva Pharms. USA, Inc., 17-0227 (D. Del.) Mar. 3, 2017 Vacant Judgeship Victoza® (liraglutide recombinant solution injection) 6,268,343; 8,114,833; 8,846,618; 9,265,893; RE41,956
Gilead Sciences, Inc. v. Mylan Pharms. Inc., 17-0036 (N.D.W.V.) Mar. 3, 2017 Hon. Irene M. Keeley Tybost® (cobicistat tablets) 8,148,374
Arena Pharms., Inc. v. Teva Pharms. USA, Inc., 17-0231 (D. Del.) Mar. 6, 2017 Hon. Richard G. Andrews Belviq XR® (lorcaserin hydrochloride tablets) 6,953,787; 7,514,422; 7,977,329; 8,207,158; 8,273,734; 8,546,379; 8,575,149; 8,999,970; 9,169,213
Wyeth LLC v. MSN Labs. Private Ltd., 17-0233 (D. Del.) Mar. 7, 2017 Hon. Richard G. Andrews Bosulif® (bosutinib tablets) 7,767,678
Dow Pharm. Sciences, Inc. v. Taro Pharms. U.S.A., Inc., 17-1568 (D.N.J.) Mar. 8, 2017 Hon. Stanley R. Chesler Onexton® (benzoyl peroxide / clindamycin phosphate topical gel) 9,561,208
Fresenius Kabi USA, LLC v. Hospira, Inc., IPR2017-01054 (PTAB) Mar. 8, 2017 N/A Precedex® (dexmedetomidine hydrochloride for injection) 8,242,158
Fresenius Kabi USA, LLC v. Hospira, Inc., IPR2017-01055 (PTAB) Mar. 8, 2017 N/A Precedex® (dexmedetomidine hydrochloride for injection) 8,338,470
Fresenius Kabi USA, LLC v. Hospira, Inc., IPR2017-01056 (PTAB) Mar. 8, 2017 N/A Precedex® (dexmedetomidine hydrochloride for injection) 8,455,527
Mylan Pharms. Inc. v. Cosmo Techs. Ltd., IPR2017-01034 (PTAB) Mar. 9, 2017 N/A Uceris® (budesonide extended-release tablets) 8,784,888
Mylan Pharms. Inc. v. Cosmo Techs. Ltd., IPR2017-01035 (PTAB) Mar. 9, 2017 N/A Uceris® (budesonide extended-release tablets) 9,320,716
Alcon Research, Ltd. v. Watson Labs., Inc., 17-0252 (D. Del.) Mar. 10, 2017 Hon. Gregory M. Sleet Pazeo® (olopatadine hydrochloride ophthalmic solution) 9,533,053
Argentum Pharms. LLC v. Alcon Research, Ltd., IPR2017-01053 (PTAB) Mar. 10, 2017 N/A Travatan Z® (travoprost ophthalmic solution) 8,268,299
Argentum Pharms. LLC v. Novartis AG, IPR2017-01063 (PTAB) Mar. 10, 2017 N/A Affinitor® (everolimus tablets) 9,006,224
West-Ward Pharms. Int’l Ltd. v. Novartis AG, IPR2017-01078 (PTAB) Mar. 13, 2017 N/A Affinitor® (everolimus tablets) 9,006,224
Alembic Pharms. Ltd. v. Novartis AG, 17-0292 (E.D. Va.) Mar. 13, 2017 Hon. Anthony J Trenga Gilenya® (fingolimod capsules) 8,324,283
Dow Pharm. Sciences, Inc. v. Actavis Labs. UT, Inc., 17-1706 (D.N.J.) Mar. 15, 2017 Hon. Stanley R. Chesler Onexton® (benzoyl peroxide / clindamycin phosphate topical gel) 9,504,704; 9,561,208
Apotex Inc. v. Symplmed Pharms., LLC, 17-0276 (D. Del.) Mar. 15, 2017 Vacant Judgeship Prestalia® (perindopril arginine / amlodipine besylate oral tablets) 6,696,481; 7,846,961
Biodelivery Sciences Int’l, Inc. v. Teva Pharms. USA, Inc., 17-0282 (D. Del.) Mar. 16, 2017 Hon. Gregory M. Sleet Bunavail® (buprenorphine / naloxone buccal film) 7,579,019; 8,147,866; 8,703,177; 9,522,188
Braintree Labs., Inc. v. Lannett Co., Inc., 17-0293 (D. Del.) Mar. 20, 2017 Hon. Gregory M. Sleet Suprep® (sodium sulfate / potassium sulfate / magnesium sulfate bowel prep kit) 6,946,149
Pfizer Inc. v. Breckenridge Pharm., Inc., 17-0302 (D. Del.) Mar. 21, 2017 Hon. Leonard P. Stark Xeljanz® (tofacitinib tablets) 6,965,027; 7,301,023
Teva Branded Pharm. Products R&D, Inc. v. Lupin Atlantis Holdings SA, 17-0307 (D. Del.) Mar. 21, 2017 Hon. Gregory M. Sleet ProAir® HFA (albuterol sulfate inhalation aerosol) 7,105,152; 8,132,712; 9,463,289
Viiv Healthcare Co. v. Lupin Ltd., 17-0315 (D. Del.) Mar. 23, 2017 Hon. Richard G. Andrews Lexiva® (fosamprenavir calcium tablets) 6,436,989
Alcon Research, Ltd. v. Lupin Ltd., 17-0321 (D. Del.) Mar. 24, 2017 Hon. Gregory M. Sleet Pazeo® (olopatadine hydrochloride ophthalmic solution) 9,533,053
UCB, Inc. v. Mylan Techs., Inc., 17-0322 (D. Del.) Mar. 24, 2017 Hon. Leonard P. Stark Neupro® (rotigotine transdermal system) 6,884,434; 7,413,747; 8,246,979; 8,246,980; 8,617,591
Eli Lilly and Co. v. Hetero USA Inc., 17-1951 (D.N.J.) Mar. 24, 2017 Hon. Kevin McNulty Cialis® (tadalafil tablets) 6,943,166
AstraZeneca Pharms. LP v. Amneal Pharms. LLC, 17-1968 (D.N.J.) Mar. 24, 2017 Hon. Renee Marie Bumb Faslodex® (fulvestrant intramuscular injection) 6,774,122; 7,456,160; 8,329,680; 8,466,139
Salix Pharms., Inc. v. Teva Pharms. USA, Inc., 17-0329 (D. Del.) Mar. 27, 2017 Hon. Gregory M. Sleet Apriso® (mesalamine extended-release capsules) 8,865,688
Lupin Ltd. v. Horizon Therapeutics, LLC, IPR2017-01159 (PTAB) Mar. 27, 2017 N/A Ravicti® (glycerol phenylbutyrate oral solution) 9,254,278
Lupin Ltd. v. Horizon Therapeutics, LLC, IPR2017-01160 (PTAB) Mar. 27, 2017 N/A Ravicti® (glycerol phenylbutyrate oral solution) 9,326,966
Bayer Healthcare LLC v. Apotex Inc., 17-0334 (D. Del.) Mar. 28, 2017 Hon. Leonard P. Stark Stivarga® (regorafenib oral tablets) 9,458,107
Pfizer Inc. v. Par Pharm., Inc., 17-0342 (D. Del.) Mar. 30, 2017 Hon. Leonard P. Stark Tikosyn® (dofetilide capsules) 6,124,363
Eli Lilly and Co. v. Actavis LLC, 17-0982 (S.D. Ind.) Mar. 30, 2017 Hon. Tanya Walton Pratt Alimta® (pemetrexed for injection) 7,772,209
Eli Lilly and Co. v. Amneal Pharms. LLC, 17-0986 (S.D. Ind.) Mar. 30, 2017 Hon. Tanya Walton Pratt Alimta® (pemetrexed for injection) 7,772,209
Galderma Labs., L.P. v. Actavis Labs. UT, Inc., 17-0903 (N.D. Tex.) Mar. 30, 2017 Hon. David C Godbey Epiduo® Forte (adapalene / benzoyl peroxide gel) 8,445,543; 8,785,420; 8,809,305
Glaxo Group Ltd. v. Teva Pharms. USA, Inc., 17-0357 (D. Del.) Mar. 31, 2017 Hon. Richard G. Andrews Flovent® HFA (fluticasone propionate metered-dose inhaler) 7,500,444; 7,832,351
Supernus Pharms., Inc. v. TWi Pharms., Inc., 17-2164 (D.N.J.) Mar. 31, 2017 Hon. Renee Marie Bumb Oxtellar XR® (oxcarbazepine extended-release tablets) 7,722,898; 7,910,131; 8,821,930; 9,119,791; 9,351,975; 9,370,525
Impax Labs., Inc. v. Sandoz Inc., 17-2227 (D.N.J.) Mar. 31, 2017 Hon. Stanley R. Chesler Rytary® (levodopa / carbidopa capsules) 7,094,427; 8,377,474; 8,454,998; 8,557,283; 9,089,607; 9,089,608; 9,463,246; 9,533,046

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.